International Stem Cell
Corp. uses it core technology, parthenogenesis, to create pluripotent human
stem cells from unfertilized eggs. By avoiding the use or destruction of viable
human embryos, the company is able to dodge ethical issues while producing
billions of human cells that can be used to research various neurological
disorders, diseases of the liver and blindness caused by corneal damage.
ISCO recently announced
the completion of a massive cell bank containing over 2.6 billion human cells,
which will allow the company to conduct clinical trials on Parkinson’s disease
in the near future. According to Ruslan Semechkin, ISCO’s Chief Scientific
Officer, the completion of the cell bank marks one of the company’s final steps
before clinical programs can begin.
The company is able to
leverage a tremendous strategic advantage over its competitors by producing
cells in its own GMP facility. “Because of the complexity involved in
manufacturing live human cell products,” stated Semechkin, “having our own GMP
facility is not only a strategic advantage, but also allows us to control the
production costs.”
The company’s
parthenogenetic stem cells present a multitude of inherent benefits. In
addition to being pluripotent, which means that they can potentially turn into
any of the body’s cells, they also inherit a duplicate set of human leukocyte
antigen (HLA) genes, which can significantly reduce the odds of rejection by
patients’ immune systems.
In the past, study of
embryonic stem cells has been severely hampered by ethical issues, and
significant research has been largely delayed or avoided. However, ISCO’s
parthenogenetic cells open the door for research on a variety of diseases and
conditions without the need for embryonic growth, which should help to quell
ethical concerns.
In addition to its own
clinical trials, ISCO also plans to generate revenue by franchising its stem
cell technology to multiple cell banks for use in scientific research in a
variety of locations. Stem cell research could lead to treatments that save
millions of lives and improve overall quality of life for millions more. As
ethical hurdles are navigated and research ramps up in the near future, ISCO is
strategically positioned to maximize on returns.
For more information,
visit www.internationalstemcell.com
About QualityStocks
QualityStocks is committed to connecting subscribers with companies that have huge potential to succeed in the short and long-term future. We offer several ways for investors to find, evaluate, and learn more about investing in these companies.
QualityStocks is committed to connecting subscribers with companies that have huge potential to succeed in the short and long-term future. We offer several ways for investors to find, evaluate, and learn more about investing in these companies.
Sign up for “The QualityStocks Daily Newsletter” at www.QualityStocks.net
The Quality Stocks Daily Blog http://blog.qualitystocks.net
The Quality Stocks Daily Videos http://videocharts.qualitystocks.net
The Quality Stocks “Ones to Watch” http://gotstocks.qualitystocks.net
Please see disclaimer on the QualityStocks website: http://disclaimer.qualitystocks.net
No comments:
Post a Comment